Dr Rebecca Bayliss
Teams and roles for Rebecca Bayliss
Publication
2025
2024
2023
2022
2021
2020
2019
2018
Articles
- Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131 , pp.1694-1706. (10.1038/s41416-024-02869-3)
- Bayliss, R. et al. 2020. Identification of host trafficking genes required for HIV-1 virological synapse formation in dendritic cells. Journal of Virology 94 (9) e01597-19. (10.1128/JVI.01597-19)
- Bayliss, R. J. et al. 2025. An αvβ6 specific precision virotherapy expressing bispecific immune cell activators induces immune cell activation and mediates tumour cell death. Molecular Therapy Oncology 33 (3) 201017. (10.1016/j.omton.2025.201017)
- Bayliss, R. J. and Parker, A. L. 2025. GP73: the key to unlocking immunotherapies efficacy in solid tumors?. Journal for ImmunoTherapy of Cancer 13 (5) e011989. (10.1136/jitc-2025-011989)
- Bayliss, R. J. and Piguet, V. 2018. Masters of manipulation: viral modulation of the immunological synapse. Cellular Microbiology 20 (10) e12944. (10.1111/cmi.12944)
- Bayliss, R. J. and Piguet, V. 2018. The ticking CLOCK of HSV-2 pathology. Journal of Investigative Dermatology 138 (1), pp.17-19. (10.1016/j.jid.2017.08.028)
- Caucheteux, S. et al., 2022. 134 Macrophage migration inhibitory factor restriction of HIV-1 trans-infection from dendritic cells to CD4+ T-cells via regulation of autophagy. Journal of Investigative Dermatology 142 (8), pp.S23-S23. (10.1016/j.jid.2022.05.140)
- Preston, H. E. et al. 2023. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation. iScience 26 (9) 107567. (10.1016/j.isci.2023.107567)
- Shimauchi, T. et al. 2019. Dendritic cells promote the spread of human T-cell leukemia virus type 1 via bidirectional interactions with CD4+ T cells. Journal of Investigative Dermatology 139 (1), pp.157-166. (10.1016/j.jid.2018.06.188)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4), pp.389-398. (10.1111/imm.13323)